The updated Medscheme specialised drug list for 2023 has been published
Reimbursement is still dependent on authorisation and benefit limits.
Some drugs included:
ANTIHEMORRHAGICS
Hemlibra
CARDIOVASCULAR SYSTEM
Volibris
DERMATOLOGICALS
Dupixent
ANTIVIRALS FOR SYSTEMIC USE
Epclusa
ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy
IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair
Recent Posts
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe
Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...
Recommendation for Teplizumab Type 1 Diabetes Routine Use
Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...
Joint Scientific Consultation EU Strategies for Medical Device Companies
The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...